FDA approved nilotinib for paediatric patients with newly diagnosed Ph+ CML-CP or Ph+ CML-CP resistant or intolerant to prior TKI

/0 Comments/in , /by

 

  • FDA approved nilotinib (TASIGNA, Novartis Pharmaceuticals Corporation) for pediatric patients 1 year of age or older with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP) or Ph+ CML-CP resistant or intolerant to prior tyrosine-kinase inhibitor (TKI) therapy. More Information.  March 22, 2018
You might also like
ASCO 2018 Breast Cancer: The ASCO18 breast cancer track summarised
Brentuximab vedotin FDA approved for pre-treated primary cutaneous anaplastic large cell lymphoma or CD30-expressing mycosis fungoides
Lenvatinib FDA approved for 1st-line treatment of HCC
FDA approved osimertinib for the 1st-line treatment of patients with EGFR exon 19 deletions or exon 21 L858R mutations positive metastatic non-small cell lung cancer (NSCLC)
Trastuzumab-biosimilar Herzuma® FDA approved in HER2+ breast cancer
Capmatinib plus gefitinib promising in MET-dysregulated NSCLC
Single-agent pembrolizumab FDA approved for the first-line treatment of stage III NSCLC with PD-L1 TPS ≥1%
Ki67 in Breast Cancer: an overview
0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *

FDA approved brentuximab vedotin plus chemotherapy for untreated stage III...Which drugs are immunotherapies?